HERM ROSENMAN
CIK 1230057 · Chief Financial Officer · last filed 2026-06-26
HERM ROSENMAN is a Chief Financial Officer who has filed 109 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing shows the insider sold $4.1M of NTRA on Jun 26, 2026. Across all open-market trades the lifetime net is −$31.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.36M
7
109
-$31.22M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NTRA | Director | 4,250 | $320.76 | $1.36M | -$28.40M | 48 | 2026-06-26 |
| DermTech, Inc. (DMTK) Delisted | Director | 134,576 | $0.09 | $12.7K | $274.6K | 8 | 2023-06-05 |
| Oxford Immunotec Global PLC (OXFD) Delisted | Director | 4,081 | — | — | $0 | 7 | 2020-06-26 |
| VIVUS INC (VVUS) Delisted | Director | 36,168 | — | — | $159.0K | 21 | 2020-02-24 |
| GPRO | Senior VP, Finance & CFO | 0 | $1.23 | $0 | -$3.25M | 17 | 2012-08-02 |
| ARYx Therapeutics, Inc. (ARYX) Delisted | Director | — | — | — | $0 | 3 | 2010-05-03 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Director | — | $0.04 | — | $0 | 1 | 2007-09-14 |
Recent Filings
109 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-26 | NTRA | Sell (S) | −16,530 | -$4.13M | EDGAR |
| 2026-06-24 | NTRA | Notice (144) | −16,530 | -$4.13M | EDGAR |
| 2026-04-28 | NTRA | Grant (A) | +339 | $0 | EDGAR |
| 2026-02-03 | NTRA | Grant (A) | +99 | $0 | EDGAR |
| 2025-12-16 | NTRA | Mixed | −48,287 | -$11.01M | EDGAR |
| 2025-12-12 | NTRA | Notice (144) | −48,419 | -$11.29M | EDGAR |
| 2025-07-29 | NTRA | Grant (A) | +153 | $0 | EDGAR |
| 2025-07-01 | NTRA | Grant (A) | +2,414 | $0 | EDGAR |
| 2025-04-29 | NTRA | Grant (A) | +164 | $0 | EDGAR |
| 2025-02-04 | NTRA | Grant (A) | +133 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.